Advanced

Evaluation of the Cerebrospinal Fluid Amyloid-beta(1-42)/Amyloid-beta(1-40) Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders

Nutu, Magdalena; Zetterberg, Henrik; Londos, Elisabet LU ; Minthon, Lennart LU ; Nägga, Katarina LU ; Blennow, Kaj; Hansson, Oskar LU and Ohrfelt, Annika (2013) In Dementia and Geriatric Cognitive Disorders 36(1-2). p.99-110
Abstract
Background: The well-established core biomarkers used to identify Alzheimer's disease (AD) overlap with other dementia disorders such as dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD). This study aimed to evaluate whether the cerebrospinal fluid (CSF) amyloid-beta (A beta)(1-42)/A beta(1-40) ratio, measured by a novel method, could improve the differential diagnosis of AD, DLB and PDD. Method: CSF levels of A beta(1-40) and A beta(1-42) in patients with PDD, DLB, AD, Parkinson's disease and controls were analyzed using an amplified luminescent proximity homogenous immunoassay along with conventional immunoassays. Results: The CSF A beta(1-42)/A beta(1-40) ratio increased discrimination of AD from PDD and DLB... (More)
Background: The well-established core biomarkers used to identify Alzheimer's disease (AD) overlap with other dementia disorders such as dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD). This study aimed to evaluate whether the cerebrospinal fluid (CSF) amyloid-beta (A beta)(1-42)/A beta(1-40) ratio, measured by a novel method, could improve the differential diagnosis of AD, DLB and PDD. Method: CSF levels of A beta(1-40) and A beta(1-42) in patients with PDD, DLB, AD, Parkinson's disease and controls were analyzed using an amplified luminescent proximity homogenous immunoassay along with conventional immunoassays. Results: The CSF A beta(1-42)/A beta(1-40) ratio increased discrimination of AD from PDD and DLB compared with either of the two A beta biomarkers individually. Conclusion: The use of the A beta(1-42)/A beta(1-40) ratio could improve the differentiation of AD from PDD and DLB. (C) 2013 S. Karger AG, Basel (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Amyloid-beta, Alzheimer's disease, Parkinson's disease, Immunoassays, Amplified luminescent proximity homogenous immunoassay
in
Dementia and Geriatric Cognitive Disorders
volume
36
issue
1-2
pages
99 - 110
publisher
Karger
external identifiers
  • wos:000328327900009
  • scopus:84880184530
ISSN
1420-8008
DOI
10.1159/000353442
language
English
LU publication?
yes
id
c496ca1d-0235-41c2-a64c-f9cafb310b55 (old id 4272598)
date added to LUP
2014-02-10 12:20:40
date last changed
2019-04-21 03:21:56
@article{c496ca1d-0235-41c2-a64c-f9cafb310b55,
  abstract     = {Background: The well-established core biomarkers used to identify Alzheimer's disease (AD) overlap with other dementia disorders such as dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD). This study aimed to evaluate whether the cerebrospinal fluid (CSF) amyloid-beta (A beta)(1-42)/A beta(1-40) ratio, measured by a novel method, could improve the differential diagnosis of AD, DLB and PDD. Method: CSF levels of A beta(1-40) and A beta(1-42) in patients with PDD, DLB, AD, Parkinson's disease and controls were analyzed using an amplified luminescent proximity homogenous immunoassay along with conventional immunoassays. Results: The CSF A beta(1-42)/A beta(1-40) ratio increased discrimination of AD from PDD and DLB compared with either of the two A beta biomarkers individually. Conclusion: The use of the A beta(1-42)/A beta(1-40) ratio could improve the differentiation of AD from PDD and DLB. (C) 2013 S. Karger AG, Basel},
  author       = {Nutu, Magdalena and Zetterberg, Henrik and Londos, Elisabet and Minthon, Lennart and Nägga, Katarina and Blennow, Kaj and Hansson, Oskar and Ohrfelt, Annika},
  issn         = {1420-8008},
  keyword      = {Amyloid-beta,Alzheimer's disease,Parkinson's disease,Immunoassays,Amplified luminescent proximity homogenous immunoassay},
  language     = {eng},
  number       = {1-2},
  pages        = {99--110},
  publisher    = {Karger},
  series       = {Dementia and Geriatric Cognitive Disorders},
  title        = {Evaluation of the Cerebrospinal Fluid Amyloid-beta(1-42)/Amyloid-beta(1-40) Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders},
  url          = {http://dx.doi.org/10.1159/000353442},
  volume       = {36},
  year         = {2013},
}